홈 › 흑색종 › 펜실베이니아 › Pittsburgh
PA Pittsburgh의 흑색종 임상 시험
흑색종 관련 연구 31개가 Pittsburgh 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
피험자 모집 중3상
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
피험자 모집 중1/2상
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
피험자 모집 중1/2상
- UPMC Hillman Cancer Center, Pittsburgh
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
피험자 모집 중1/2상
- UPMC Hillman Cancer Center, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
피험자 모집 중1/2상
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
피험자 모집 중1/2상
- Research Site, Pittsburgh
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
피험자 모집 중3상
- Allegheny Health Network, Pittsburgh
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
피험자 모집 중2상
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
피험자 모집 중3상
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
피험자 모집 중2상
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Project: Every Child for Younger Patients With Cancer
피험자 모집 중관찰 연구
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
피험자 모집 중1/2상
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Investigating Real-Time Immunotherapy Symptoms Study
피험자 모집 중
- UPMC Hillman Cancer Center, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
피험자 모집 중2상
- UPMC Hillman Cancer Center, Pittsburgh
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
피험자 모집 중관찰 연구
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
피험자 모집 중1/2상
- UPMC Hillman Cancer Center, Pittsburgh
Evaluation of Hypoxia in Primary Melanoma
피험자 모집 중관찰 연구
- UPMC Hillman Cancer Center, Pittsburgh
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
피험자 모집 중1/2상
- University of Pittsburgh Medical Center, Pittsburgh
Neoadjuvant Darovasertib in Primary Uveal Melanoma
피험자 모집 중3상
- UPMC Hillman Cancer Center, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
피험자 모집 중1/2상
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
피험자 모집 중1상
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
피험자 모집 중2상
- UPMC Hillman Cancer Center, Pittsburgh
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
피험자 모집 중초기 1상
- UPMC Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
피험자 모집 중1상
- UPMC- Hillman Cancer Center, Pittsburgh
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
피험자 모집 중2/3상
- UPMC Hillman Cancer Center, Pittsburgh
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
피험자 모집 중3상
- UPMC Hillman Cancer Center, Pittsburgh
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
피험자 모집 중관찰 연구
- UPMC Hillman Cancer Center, Pittsburgh
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
피험자 모집 중1/2상
- University of Pittsburgh Medical Center, Pittsburgh
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
피험자 모집 중1/2상
- University of Pittsburgh Medical Center, Pittsburgh
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
피험자 모집 중1/2상
- UPMC Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
피험자 모집 중1/2상
- University of Pittsburgh, Pittsburgh
다른 도시의 흑색종 시험
- Houston, TX연구 61개
- New York City, NY연구 41개
- Nashville, TN연구 34개
- Los Angeles, CA연구 34개
- Boston, MA연구 25개
- St. Louis, MO연구 23개
- Durham, NC연구 22개
- Philadelphia, PA연구 22개
- Tampa, FL연구 21개
- Columbus, OH연구 21개
- Dallas, TX연구 21개
- San Francisco, CA연구 21개
Pittsburgh의 다른 연구
- 비소세포폐암연구 47개
- 암 (전체)연구 42개
- 유방암연구 42개
- 난소암연구 32개
- 대장직장암연구 31개
- 전이성 암연구 31개
- 자궁내막암연구 24개
- 폐암연구 24개
- 두경부 편평세포암연구 23개
- 전립선암연구 23개
- 우울증연구 22개
- 뇌졸중연구 21개
ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.